An observational study in Multiple Sclerosis, Caregiver Burden and Sleep Quality, sponsored by Süleyman Korkusuz. Not yet recruiting at 1 site in Turkey (Türkiye). Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Süleyman Korkusuz · Observational
Among 307 studies in Multiple Sclerosis with a site in Turkey — 59 open to participants now, 78 under way, 10 of them phase 3. Multiple Sclerosis · Turkey.
Among the 307 studies in Multiple Sclerosis with a site in Turkey, this one is the 43rd largest by planned enrollment of the 103 observational ones, is one of 43 that started in 2026, is one of 103 observational ones, reaches primary completion later than 61 of the 77 other live ones, and was the 302nd registered.
3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.
This study's planned enrollment of 68 is below the median of 100 across 970 observational studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →59 of the 307 studies in Multiple Sclerosis with a site in Turkey are open now, in 11 countries. Each count lists the studies.
Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →307 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 43 started in 2026.
Median enrollment 40 across the 204 interventional studies, 60 across the 103 observational. Of the 204 that completed or were terminated, 37 (18%) have results posted.
52 of 307 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Süleyman Korkusuz as lead sponsor.
Süleyman Korkusuz has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
17 of the studies in Multiple Sclerosis with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07137624Hacettepe UniversityMotor Imagery and Action Observation for Gait Function in MS | 2026-11 |
| NCT07571304Istanbul University - CerrahpasaDual-Task Training in Pediatric Multiple Sclerosis | 2026-12-01 |
| NCT07842731Atılım UniversityInvestigation of the Prevalence of Sarcopenia and Dynapenia According to Disease Stage in Patients With Multiple Sclerosis and Evaluation of the Relationship Between Sarcopenia Severity and Clinical and Functional Parameters | 2026-12-10 |
| NCT06777134Berivan Beril KılıçRelationship Between Pelvic Floor Dysfunctions and Lower Limb Strength and Activation in MS Patients | 2026-12-10 |
Among the 307 studies in Multiple Sclerosis with a site in Turkey, from their registry updates:
This cross-sectional observational study aims to investigate the associations between multiple sclerosis (MS) severity and caregivers' sleep quality, physical activity, body awareness, perceived stress, and caregiver burden. A total of 68 caregivers of patients with MS will be recruited from Başkent University Hospital. MS severity will be assessed using the Expanded Disability Status Scale (EDSS), while caregiver health outcomes will be evaluated using validated questionnaires. The findings are expected to provide insight into the multidimensional impact of MS severity on caregiver health and well-being.
This cross-sectional observational study aims to investigate the associations between multiple sclerosis (MS) severity and caregivers' sleep quality, physical activity, body awareness, perceived stress, and caregiver burden.
A total of 68 caregivers of individuals with MS will be included. Disease severity will be assessed using the Expanded Disability Status Scale (EDSS). Caregiver outcomes will be evaluated using the Pittsburgh Sleep Quality Index (PSQI), International Physical Activity Questionnaire-Short Form (IPAQ-SF), Body Awareness Questionnaire (BAQ), Perceived Stress Scale (PSS), and Zarit Burden Interview (ZBI).
The study will examine the relationships between MS severity and caregiver health outcomes within the framework of the International Classification of Functioning, Disability and Health (ICF). No therapeutic intervention will be administered.
The study population will consist of 68 adult caregivers of individuals diagnosed with multiple sclerosis who receive care at Başkent University Hospital. Caregivers will be recruited to evaluate the associations between MS severity and caregiver health outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult caregivers who have provided regular care to a person diagnosed with multiple sclerosis for at least six months.
Caregiver Burden (Zarit Burden Interview)
Caregiver burden will be assessed using the Zarit Burden Interview (ZBI). Higher scores indicate greater perceived caregiver burden.
Time frame: Baseline
Sleep Quality (Pittsburgh Sleep Quality Index)
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). Total scores range from 0 to 21, with higher scores indicating poorer sleep quality. Scores above 5 indicate poor sleep quality.
Time frame: Baseline
Physical Activity (IPAQ-SF)
Physical activity will be assessed using the International Physical Activity Questionnaire-Short Form (IPAQ-SF). Total physical activity will be expressed as metabolic equivalent of task minutes per week (MET-min/week) based on activities performed during the previous seven days. Total MET-min/week is calculated as the sum of walking (3.3 METs × minutes × days), moderate-intensity activity (4.0 METs × minutes × days), and vigorous-intensity activity (8.0 METs × minutes × days). The minimum possible value is 0 MET-min/week; there is no fixed maximum score. Higher MET-min/week values indicate a higher level of physical activity and therefore a better outcome.
Time frame: Baseline
Body Awareness (Body Awareness Questionnaire)
Body awareness will be assessed using the 18-item Body Awareness Questionnaire (BAQ). Each item is rated on a 7-point Likert scale from 1 to 7, yielding a total score ranging from 18 to 126. Higher scores indicate greater body awareness and therefore a better outcome
Time frame: Baseline
Perceived Stress (Perceived Stress Scale)
Perceived stress will be assessed using the 10-item Perceived Stress Scale (PSS-10). Total scores range from 0 to 40, with higher scores indicating greater perceived stress.
Time frame: Baseline
Plan to share: No
Start is estimated for Oct 2026; primary completion for Jan 2027, 3 months later.
Of 334 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 73. This study's planned 3 months is below that.
Counting every sponsor, half of 425 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.